Articles tagged with Rheumatoid Arthritis
Research shows that many patients with RA, spondyloarthritis, and other inflammatory joint diseases are not receiving adequate CVD-preventive medications, despite being at high risk. Only half of those who start treatment achieve their goals, highlighting a significant need for improvement in CVD prevention.
A study of 9,362 surgeries on 5,544 RA patients found that continuing DMARDs prior to surgery does not increase post-operative infection risk. Researchers recommend considering medication continuation during the perioperative period to maintain better control over RA and reduce complications.
Researchers found distinct monocyte gene expression signatures in RA patients with different responses to anti-TNF therapy, potentially leading to personalized treatment approaches.
Researchers found that patients treated with rituximab as their first biologic had a lower mortality risk compared to those treated with TNFi. The study included 353 patients with RA-ILD and analyzed five-year mortality rates, with RTX-treated patients showing numerically lower but not statistically significant risks.
Researchers identified three gene expression signatures that can help rheumatologists predict which patients are more likely to respond to certain therapies. The findings could lead to higher response rates and reduced likelihood of ineffective treatment, ultimately improving patient care.
Researchers found that people with RA have double the risk of CV events as those in the general population, rates similar to those with type-2 diabetes. Chronic inflammation in RA contributes independently to cardiovascular risks for these patients.
Early and aggressive treatment with biologic drugs may halt progressive bone loss in patients with RA. Biologic therapies targeting specific cytokines and signaling pathways show protective effects on the skeleton.
Researchers at the University of Warwick have developed a blood test to detect early-stage osteoarthritis (OA) and distinguish it from other self-resolving inflammatory joint diseases. The test identifies biomarkers in plasma proteins damaged by oxidation, nitration, and glycation, enabling early detection and treatment.
Researchers at Mayo Clinic have identified intestinal bacteria as a possible cause of rheumatoid arthritis and found a link between specific microbiota and the disease. Testing for certain gut bacteria may help predict and prevent rheumatoid arthritis, with potential applications in personalized treatment.
Researchers found that an extra-low dose combination of two anticytokines reduced rheumatoid arthritis disease activity and cardiovascular events. The study showed a lower incidence of cardiovascular events in patients treated with the combination, suggesting decreased cardiovascular risk.
A new study published in PNAS shows that vagus nerve stimulation significantly improves measures of disease activity in patients with rheumatoid arthritis. The treatment, which involves stimulating the vagus nerve with an implantable device, has been shown to inhibit cytokine production and attenuate disease severity in humans.
A recent review by University of Alberta researchers found little evidence to support the benefits of vitamin D supplementation for various health conditions. Strongest effects were seen in reducing falls and fractures among the elderly. Moderate supplementation is unlikely to cause harm but will not lead to significant health benefits.
Studies reveal distinct differences in key cellular processes and molecular signatures between rheumatoid arthritis (RA) and osteoarthritis (OA), as well as joint-specific variations in RA. These findings may enable precise targeting of treatment for each ailing joint, explaining why drugs vary in effect.
A new study reveals that prolonged repetitive physical workload increases the risk of developing rheumatoid arthritis, with certain types of work increasing the odds more than others. The study also found a significant interaction between genetic makeup and physical workload in relation to the development of RA.
A study presented at EULAR 2016 found that a combination of text messages and individual counselling sessions motivated patients with Rheumatoid Arthritis to be more active, resulting in reduced daily sitting time and improved cholesterol levels. This behavioural intervention was effective in improving patient-reported clinical outcomes.
A study found that over one-third of active rheumatoid arthritis patients suffer from sexual problems, including low libido and painful intercourse. Factors contributing to these issues include lack of attraction, anxiety, and relationship problems.
Two studies presented at EULAR 2016 found that patients with positive expectations and autonomy are more likely to adhere to their treatment. Non-adherence is associated with factors such as anxiety, depression, and negative feelings, highlighting the need for strategies to improve treatment adherence.
A study presented at EULAR 2016 found that UK rheumatologists often deviate from NICE guidance on cost when treating RA patients, citing clinical autonomy and patient involvement as key factors. The study suggests that further research is needed to explore the impact of these deviations on patient outcomes and cost-effectiveness.
A recent study found that patients with rheumatoid arthritis who are obese and smoke have a lower chance of achieving sustained remission after treatment. Encouraging patients to quit smoking and maintain a healthy weight could improve their symptoms. The findings highlight the importance of lifestyle factors in managing the disease.
A recent study published at EULAR 2016 found that patients with osteoarthritis (OA) are more likely to have their condition underestimated by rheumatologists than those with rheumatoid arthritis (RA). The study highlighted the importance of understanding the impact of disease severity on treatment compliance and future outcomes. Resear...
Researchers have developed nanoparticles that can selectively deliver drugs to inflamed joint tissue, improving tolerability and reducing treatment costs. This breakthrough offers new hope for patients with rheumatoid arthritis, allowing for early diagnosis and targeted therapy.
A survey of over 3,600 adults with RA found that patients value patient participation in multidisciplinary team conferences, leading to better outcomes. Patients want more involvement in treatment planning, with 70% satisfied but desiring fewer medications and more choices.
Hospitalizations related to gout have increased dramatically, reflecting rising incidence and persistent suboptimal care. In contrast, hospitalizations for rheumatoid arthritis have dropped considerably over the past two decades due to improved management and treatment.
HUMIRA enhances the function of TNF in rheumatoid arthritis patients by increasing its expression on monocytes and promoting membrane-bound TNF-RII binding. This leads to the activation of anti-inflammatory T cells that can suppress inflammation.
Rheumatoid arthritis patients are at risk of developing hearing impairment due to various factors such as synovial destruction and environmental exposures. Regular audiometric tests and TEOAEs can detect early stages of the disease, and treatment options include oral steroids and intensifying Disease-Modifying Antirheumatic Drugs.
Researchers discovered that resolvin D1 promotes cartilage repair and reduces joint damage in mouse models of inflammatory arthritis. Administration of resolvin D1 dramatically reduced disease symptoms and promoted remission.
Researchers have discovered how compounds produced by the body's immune system help to dampen inflammation and prevent damage to healthy tissues. These compounds, called alpha defensins, may act on cells of the immune system to prevent excessive inflammation.
A phase-3 trial led by Stanford University shows baricitinib substantially reduces symptoms and improves daily functioning in refractory rheumatoid arthritis patients. The study, involving over 500 adults, found that baricitinib improved physical function and reduced markers of inflammation, with effects remaining at 24 weeks.
Researchers discovered that prooxidants can repair a metabolic flaw in T cells that drive rheumatoid arthritis. Treating arthritic mice with ROS-inducing drugs restored the T cells' redox balance and reduced joint inflammation.
A study in the American Journal of Pathology finds that serotonin deficiency is associated with worse rheumatoid arthritis (RA) symptoms and pathology in mice. Serotonin or its agonists can reduce RA effects, suggesting a new therapeutic target for this debilitating disease.
Researchers identified a potential new approach to combating rheumatoid arthritis by blocking the effects of the disease using epigallocatechin-3-gallate (EGCG), a molecule with anti-inflammatory properties found in green tea. The compound markedly reduced ankle swelling in an animal model of human rheumatoid arthritis.
Researchers at NIH/NIEHS discovered that increasing tristetraprolin (TTP) levels in mice significantly reduced or protected against inflammation. TTP may offer an effective treatment for inflammatory diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Research finds occupational textile dust exposure associated with a more than doubling in rheumatoid arthritis risk. Genetic susceptibility to ACPA antibodies is also linked, with those exposed nearly three times as likely to develop the disease.
Scientists have discovered a blood test that can predict rheumatoid arthritis (RA) in some individuals even 16 years before the condition takes effect. The test detects antibodies targeting citrullinated tenascin-C, which were found in high levels in joints of people with RA.
Deaths from cardiovascular disease among people with rheumatoid arthritis are declining, according to a new study. Researchers found that efforts to prevent and diagnose heart problems may be paying off for patients with the chronic condition.
Pfizer announces new scientific abstracts and presentations for XELJANZ (tofacitinib citrate) in rheumatoid arthritis, including safety data, long-term extension studies, and real-world evaluation. The data highlights the efficacy and safety of XELJANZ in treating RA.
Researchers found that rheumatoid arthritis significantly increases participants' overall risk of death, especially due to respiratory or cardiovascular causes. Seropositive RA was associated with a nearly three-fold increased risk of respiratory mortality compared to seronegative RA.
Scientists at Cardiff University have discovered a key protein that regulates inflammation in rheumatoid arthritis, enabling the development of tailored treatment plans. This breakthrough has the potential to improve disease outcomes and quality of life for patients with this debilitating condition.
A high body mass index (BMI) is linked to a lower risk of rheumatoid arthritis (RA) in men, but not women, according to a Swedish study. The association was strongest in men with increased abdominal obesity or visceral fat.
A new protein (C5orf30) has been identified as a genetic marker that can help regulate the severity of tissue damage caused by rheumatoid arthritis. This discovery enables early identification of patients at risk of severe joint damage, allowing for fast-tracked treatment with more aggressive therapies.
A new protein (C5orf30) has been identified as a genetic marker for rheumatoid arthritis severity, allowing for early diagnosis and targeted treatment. This breakthrough discovery has the potential to improve patient outcomes and reduce tissue damage caused by the condition.
Research reveals that depressive symptoms, stress, anxiety, and anger are associated with increased atherosclerosis markers in RA patients. Screening and treatment of psychosocial symptoms may curb the cardiovascular disease burden in this patient group.
Researchers link positive and negative mood to daily pain in rheumatoid arthritis patients, suggesting that interventions targeting depression and momentary mood may improve pain and quality of life. The study's findings may have implications for individuals with chronic pain beyond rheumatoid arthritis.
A metagenome-wide association study uncovered markers in the oral and gut microbiomes that are associated with rheumatoid arthritis (RA). The study found that Haemophilus sp. is depleted in RA patients and Lactobacillus salivarius is over-represented, suggesting potential new targets for diagnosis and treatment.
Researchers found that total knee replacement reduces knee pain and improves subjective quality of life indices in rheumatoid arthritis patients. However, improvements were not as great as those experienced by osteoarthritis patients.
A study has identified a potential link between inflammation caused by rheumatoid arthritis and the development of heart valve disease, including aneurysms. The research team hopes that existing medicines that dampen inflammation could be repurposed to treat heart valve diseases.
A new study found that a test can predict which rheumatoid arthritis patients will fail to respond to biologic drugs. Detecting low drug levels and anti-drug antibodies in the bloodstream can help adjust treatments.
Studies found increased incidents of rheumatoid arthritis and giant cell arteritis in concert with the cycle of magnetic activity of the sun. Correlations were strongest between diseases and geomagnetic activity, with GCA incidence peaking within one year of intense geomagnetic activity.
A dose reduction strategy for TNF inhibitors can maintain good clinical response in RA patients even when the dose is reduced by one-third. Reducing the dose by two-thirds results in more flares, but these subsided when the higher dose was restarted.
Early RA patients exhibit cardiomyopathy, reduced vascular function, and increased cardiovascular mortality. Cardiac MRI revealed aortic stiffness, left ventricular volumes, and geometry changes indicative of cardiac abnormalities.
A systematic review of 15 randomized controlled trials found that biologics significantly reduce accumulated missed workdays and improve work productivity among patients with rheumatic diseases. This suggests a potential economic benefit to treating these conditions.
Two studies show ultrasound can identify RA patients in clinical remission with active subclinical synovitis, highlighting the risk of progressive joint damage. High-resolution ultrasound diagnoses active subclinical synovitis identifies patients who benefit from more intensive treatment.
A study found that people with rheumatoid arthritis are less protected by the hepatitis B vaccine, highlighting increased risk of infection despite vaccination. The vaccine's efficacy was lower in RA patients compared to those without the condition.
Fatigue remains a debilitating problem for RA patients, with healthcare professionals often failing to measure it. New guidelines recommend validated fatigue measurements to improve patient outcomes. In contrast, treatment aimed at achieving disease remission is unlikely to be effective in addressing fatigue.
A study found that RA patients with moderate disease activity are at risk of needing joint surgery, challenging existing treatment guidelines. The findings suggest updating disease activity cut-off points to allow moderate-disease-activity patients to receive biologics.
The tREACH trial found that combination DMARDs (methotrexate, sulfasalazine, and hydroxychloroquine) improve measures of disease activity and functional ability in patients with early rheumatoid arthritis. This suggests an earlier decrease in disease severity and improvements in functional ability compared to monotherapy.
A study presented at EULAR 2015 found that ultrasound diagnosis of tenosynovitis was superior to clinical symptoms in predicting early RA. This procedure has the potential to improve clinical outcomes by identifying the need for treatment before symptom onset.
A world-first vaccine-style therapeutic approach has demonstrated safety and effectiveness in suppressing the immune response in a phase one clinical trial for rheumatoid arthritis. The treatment targets high-risk genes and antibodies associated with the disease.,
A recent UK study found that 40% of rheumatoid arthritis patients scored low on an adherence questionnaire, indicating inconsistent medication use. The research highlights the need for healthcare professionals to better inform patients about the importance of taking drugs as prescribed.
A team of researchers from Montana State University has identified a new chemical compound called IQ-1S that shows promise in treating rheumatoid arthritis. The study found that IQ-1S significantly reduced the severity of collagen-induced arthritis and inhibited the destruction of cartilage and bone.